Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Community healthcare charities receive £300,000 from GlaxoSmithKline in recognition of their work
20 charities were formally acknowledged last night for their community-based work, as GSK awards, run in partnership with The King's Fund.
-
GlaxoSmithKline to divest US rights for Wellbutrin XL® to Biovail for $510 million
GSK in agreement to divest full commercial rights for Wellbutrin to BVF for $510 million, subject to Hart-Scott-Rodino clearance in US.
-
GlaxoSmithKline update: influenza A (H1N1)
GSK committed to supporting governments and health authorities around the world to respond to the emergence of the new H1N1 strain.
-
Large, long-term study shows dutasteride reduced prostate cancer risk in men at increased risk of the disease
Primary endpoint achieved in REDUCE study as presented at American Urological Association
-
Emergence of a new H1N1 influenza A strain (swine influenza)
GSK is closely monitoring H1N1 strain in Mexico, US, Canada, France, Spain & New Zealand. WHO stated, situation a cause for concern.
-
GlaxoSmithKline launches alli® (orlistat 60 mg)
GSK announced, first clinically proven over the counter weight loss aid is available in pharmacies across Europe.
-
GlaxoSmithKline and Stiefel to create new world-leading specialist dermatology business
Stiefel, the world's largest independent dermatology company, acquired by GSK in deal valued at up to $3.6 billion.
-
GlaxoSmithKline and Pfizer announce innovative agreement to create a new world-leading, specialist HIV company
Creates a new focused HIV business with the sustainability to deliver significant improvements in treatment, access and shareholder value.
-
GSK submits Tyverb®/Tykerb® (lapatinib) for first-line treatment of metastatic breast cancer in Europe, US
GSK announced, submission of 2 applications to expand the use of lapatinib, therapy regimen for metastatic breast cancer.
-
Synflorix™, GlaxoSmithKline’s pneumococcal vaccine, receives European authorisation
Protection now possible against three pneumococcal strains not covered by currently available vaccine.
-
Cervarix® U.S. regulatory update
GlaxoSmithKline submits final study data to FDA for cervical cancer vaccine
-
GSK publishes 2008 Corporate Responsibility Report
Details on new proposals to tackle diseases of the developing world.
-
GlaxoSmithKline announces sale of shares in Quest Diagnostics Inc.
GSK announces it's sold 5,749,157 shares of common stock, par value of $0.01 per share of Quest Diagnostics Inc.
-
GlaxoSmithKline submits European marketing authorisation application for Pazopanib in advanced kidney cancer
GSK announced submission of MAA to EMEA for pazopanib, oral therapy for metastatic renal cell carcinoma (RCC).
-
NICE refuses funding for advanced breast cancer treatment, Tyverb® (lapatinib)
NICE issued appraisal against NHS funding for Tyverb, treatment for breast cancer (ErbB2-positive).1.
-
GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)
GSK announced start of the Phase III clinical trial programme of GLP-1 agonist Syncria in men and women with type 2 diabetes.
-
GlaxoSmithKline and Idenix Pharmaceuticals sign worldwide license agreement for IDX899, a novel NNRTI for the treatment of HIV
GSK & Idenix announced agreement granting GSK exclusive worldwide rights to IDX899, a NNRTI in Phase II, treatment of HIV/AIDS.
-
GlaxoSmithKline and Genmab seek European marketing authorisation of Arzerra™ (ofatumumab) in advanced stage blood cancer
GSK & Genmab announced submission of MAA to EMEA for Arzerra, treatment of CLL, it targets a binding site on the CD20 molecule of B-cells.
-
Results announcement for the fourth quarter 2008
See the quarterly results page for more information.
-
GSK and Theravance announce positive phase 2b results for once-daily fluticasone furoate in the treatment of asthma
Data increase confidence in the Horizon development programme